Abstract:Park et al1Park S.W. Lee K.J. Chung M.J. et al.Covered versus uncovered double bare self-expandable metal stent for palliation of unresectable extrahepatic malignant biliary obstruction: a randomized controlled multicenter trial.Gastrointest Endosc. 2023; 97: 132-142.e2Abstract Full Text Full Text PDF Scopus (2) Google Scholar reported no significant differences in the 6-month stent patency rates and mortality between partially covered and uncovered double bare self-expandable metal stents (PCDBSs vs UCDBSs) for unresectable distal malignant biliary obstruction. This randomized controlled multicenter trial is of great significance for clinical practice, yet we would like to share our reservations for further research. First, as shown in the baseline characteristics section, the length of the stricture was longer in PCDBSs than in UCDBSs (2.8 ± 1.3 vs 2.4 ± 1.2, P = .010). The length or the degree of stricture might be correlated with disease severity and stent patency,2Kim H.S. Lee D.K. Kim H.G. et al.Features of malignant biliary obstruction affecting the patency of metallic stents: a multicenter study.Gastrointest Endosc. 2002; 55: 359-365Abstract Full Text Full Text PDF PubMed Scopus (92) Google Scholar and longer biliary stricture was an independent risk factor for worse survival after metal stent insertion,3Zu Q.Q. Zhang J.X. Wang B. et al.Percutaneous transpapillary biliary stent placement for distal malignant biliary obstruction: outcomes and survival analysis.Turk J Gastroenterol. 2019; 30: 714-721Crossref Scopus (5) Google Scholar which is also in accord with the fact that the rate of tumor overgrowth was higher in the PCDBS group than in the UCDBS group (5.5% vs 0.8%). Therefore, we hypothesize that the PCDBS group had selection bias, which would weaken the effect of PCDBSs on stent patency and overall survival, and a propensity-matching analysis may be required. Second, we would like to know whether there was a significant difference in the total incidence of single adverse events between the 2 groups, regardless of the 2-week time limit, so as to better verify the overall impact of whether or not the novel metal stent is covered on the risk of adverse events.4Dumonceau J.M. Kapral C. Aabakken L. et al.ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) guideline.Endoscopy. 2020; 52: 127-149Crossref PubMed Scopus (331) Google Scholar Third, the authors did not disclose the details of revision for stent dysfunction, which might have had some influence on stent patency and overall survival. For example, radiofrequency ablation can be performed by both endoscopic and percutaneous routes. As a novel adjunctive procedure and a promising therapeutic option in patients with malignant biliary obstruction, radiofrequency ablation can achieve local tumor control, resulting in improved biliary stent patency and a potential survival benefit.5Inoue T. Yoneda M. Updated evidence on the clinical impact of endoscopic radiofrequency ablation in the treatment of malignant biliary obstruction.Dig Endosc. 2022; 34: 345-358Crossref PubMed Scopus (22) Google Scholar Both authors disclosed no financial relationships.

Novel self-expandable stent-based endobiliary radiofrequency ablation for unresectable malignant biliary obstruction

Feasibility and Safety of Endoluminal Radiofrequency Ablation as a Rescue Treatment for Bilateral Metal Stent Obstruction Due to Tumor Ingrowth in the Hilum: A Pilot Study

Intrabiliary Radiofrequency-Enhanced Local Chemotherapeutic Deposit in Bile Duct Walls Using a Needle-Integrated Balloon Catheter: A Feasibility Study on Survival Pigs

Local palliative therapies for unresectable malignant biliary obstruction: radiofrequency ablation combined with stent or biliary stent alone? An updated meta-analysis of nineteen trials

Impact of temperature-controlled endobiliary radiofrequency ablation for inoperable hilar cholangiocarcinoma: A propensity score-matched analysis

Endoscopic radiofrequency biliary ablation treatment: A comprehensive review

Percutaneous endobiliary radiofrequency ablation and stent placement for unresectable malignant biliary obstruction: a propensity score matching retrospective study

Endobronchial Ultrasound-Guided Radiofrequency Ablation of Lung Tumors and Mediastinal Lymph Nodes: A Preclinical Study in Animal Lung Tumor and Mediastinal Adenopathy Models

Clinical feasibility of radiofrequency ablation using novel adjustable separable electrodes with a multipurpose needle for treating small hepatocellular carcinomas: a prospective single center study

Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma

Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial

[Experimental Study of Radiofrequency Ablation of Liver in Swine].

Percutaneous Intraductal Radiofrequency Ablation For Treatment Of Biliary Stent Occlusion: A Preliminary Result

[Preliminary Clinical Study of Percutaneous Transhepatic Bipolar Radiofrequency Ablation Catheter in the Treatment for Malignant Biliary Obstructive Jaundice and Biliary Stent Re-Stenosis].

Adjuvant endobiliary radio-frequency ablation combined with self-expandable biliary metal stents for unresectable malignant hilar strictures: A pragmatic comparative study

Double Bare Self-Expandable Metal Stent for Distal Malignant Biliary Obstruction.

Percutaneous transhepatic cholangiography: An effective option for endo-biliary radiofrequency ablation before stent insertion in unresectable biliary cancer?

Intrabiliary RF Heat-Enhanced Local Chemotherapy of a Cholangiocarcinoma Cell Line: Monitoring with Dual-Modality Imaging--preclinical Study.

Percutaneous Intraductal Radiofrequency Ablation for the Treatment of Biliary Stent Stenosis：a Preliminary Study

Endoscopic radiofrequency ablation plus plastic stent placement versus stent placement alone for unresectable extrahepatic biliary cancer: a multicenter randomized controlled trial

Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial